BridgeBio’s mission is to find, develop, and deliver breakthrough medicines for genetic diseases to patients as quickly and safely as possible. The company creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.
MyoKardia is pioneering a precision medicine approach to discover, develop, and commercialize targeted therapies for the treatment of serious cardiovascular diseases. MyoKardia’s scientists have discovered a portfolio of small molecule therapeutics aimed at the muscle proteins of the heart and intended to correct the excessive contraction, impaired relaxation, or insufficient contraction underlying diseases of systolic and diastolic dysfunction.
Navire, an affiliate of BridgeBio Pharma, is harnessing advances in the understanding of the role of SHP2 (Src homology region 2-containing protein tyrosine phosphatase) in cancer signaling to develop novel therapies for rare and difficult-to-treat cancers. The company develops small molecules inhibitors to SHP2, a phosphatase that mediates signaling of multiple pathways harnessed by tumors, thereby decreasing tumor growth while also enhancing patients’ immune response.
QED, an affiliate of BridgeBio Pharma, focuses on precision medicine for FGFR-driven cancers and diseases. QED, derived from the Latin “Quod Erat Demonstrandum” means “Thus, It Has Been Proven.” The company is focused on the development of infigratinib, a selective FGFR1-3 inhibitor.